NewLink Genetics (NASDAQ: NLNK) is one of 187 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare NewLink Genetics to related companies based on the strength of its risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
This is a breakdown of recent ratings for NewLink Genetics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|NewLink Genetics Competitors||537||2436||6629||127||2.65|
Insider and Institutional Ownership
52.7% of NewLink Genetics shares are held by institutional investors. Comparatively, 47.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 13.7% of NewLink Genetics shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
NewLink Genetics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, NewLink Genetics’ rivals have a beta of 1.58, indicating that their average share price is 58% more volatile than the S&P 500.
This table compares NewLink Genetics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|NewLink Genetics Competitors||-4,539.44%||-565.97%||-42.75%|
Valuation and Earnings
This table compares NewLink Genetics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|NewLink Genetics||$35.77 million||-$85.15 million||-3.34|
|NewLink Genetics Competitors||$217.29 million||-$39.39 million||-66.48|
NewLink Genetics’ rivals have higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
What are top analysts saying about NewLink Genetics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NewLink Genetics and related companies.